# MC200708 Pemetrexed and Pembrolizumab for the Treatment of Recurrent and/or Metastatic Salivary Gland Cancer

> **NCT04895735** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Mayo Clinic** · enrollment: 45 (actual)

## Conditions studied

- Metastatic Salivary Gland Carcinoma
- Recurrent Salivary Gland Carcinoma
- Stage IV Major Salivary Gland Cancer AJCC v8
- Adenoid Cystic Carcinoma

## Interventions

- **BIOLOGICAL:** Pembrolizumab
- **DRUG:** Pemetrexed Disodium
- **PROCEDURE:** Biospecimen Collection
- **PROCEDURE:** Computed Tomography
- **PROCEDURE:** Positron Emission Tomography
- **PROCEDURE:** Magnetic Resonance Imaging
- **PROCEDURE:** PSMA PET Scan

## Key facts

- **NCT ID:** NCT04895735
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-07-23
- **Primary completion:** 2025-08-13
- **Final completion:** 2028-02-28
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2026-02-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04895735

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04895735, "MC200708 Pemetrexed and Pembrolizumab for the Treatment of Recurrent and/or Metastatic Salivary Gland Cancer". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT04895735. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*